LOX-1: A potential target for therapy in atherosclerosis; an in vitro study

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Immunology

Background:

• Oxidized low-density lipoprotein (oxLDL) interaction with the Lectin-like oxidized LDL receptor 1 (LOX-1) triggers pro-inflammatory signals.
• Sustained LOX-1 signaling contributes to atherosclerosis development.
• Novel therapeutic strategies are needed to attenuate oxLDL-induced inflammation.

Purpose of the Study:

• To investigate the temporal dynamics of LOX-1 signaling.
• To identify key mediators in the oxLDL-LOX-1 pathway.
• To evaluate the efficacy of a novel siRNA (siLOX-1Ω) in attenuating LOX-1 signaling.

Main Methods:

• A metabolic pulse-chase system was used to study LOX-1R signaling over 72 hours.
• Cells were treated with oxLDL and then chased without the stimulus.
• Expression of LOX-1R, TNF-α, IL-6, NO, and NF-kB was measured.
• A novel combination siRNA (siLOX-1Ω) was employed to target Homo sapien LOX-1 mRNA.

Main Results:

• LOX-1R expression showed a biphasic pattern, increasing initially and then renewing after 48 hours.
• Tumor necrosis factor-alpha (TNF-α) acted as a primary mediator, potentially stimulating CD40 and MMP-9.
• Interleukin-6 (IL-6) and TNF-α were involved in the second phase of signaling, peaking at 48 hours.
• siLOX-1Ω effectively reduced LOX-1R expression and downstream signaling intermediates like nitric oxide (NO) and nuclear factor-kappa B (NF-kB).

Conclusions:

• LOX-1 signaling is sustained by pro-inflammatory cytokines even after oxLDL withdrawal.
• siLOX-1Ω successfully abated LOX-1R expression and its associated inflammatory cascade.
• Targeting LOX-1 signaling via siLOX-1Ω presents a potential therapeutic avenue for atherosclerosis.